As of July 2025, many Aetna standard commercial plans stopped covering Zepbound for weight loss
Retatrutide: Designed to Last One of the newest GLP-1 medications in development is retatrutide , a triple agonist (GLP-1, GIP, and glucagon receptors) designed with an approximate 6-day half-life , thanks to advanced pharmaceutical engineering
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al
Because compounded drugs do not have the guardrails, nor have they been tested in large populations, there are risks associated with them, and they therefore should never be produced on a mass marketing basis except in very limited situations where the FDA has declared a shortage of drugs in high demand
They make it easier to eat less and feel satisfied, but they dont do the work for you